CA2524818A1 - Peptides de proteine kinase c utilises pour le sevrage - Google Patents

Peptides de proteine kinase c utilises pour le sevrage Download PDF

Info

Publication number
CA2524818A1
CA2524818A1 CA002524818A CA2524818A CA2524818A1 CA 2524818 A1 CA2524818 A1 CA 2524818A1 CA 002524818 A CA002524818 A CA 002524818A CA 2524818 A CA2524818 A CA 2524818A CA 2524818 A1 CA2524818 A1 CA 2524818A1
Authority
CA
Canada
Prior art keywords
peptide
seq
pkc
withdrawal
isozyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002524818A
Other languages
English (en)
Inventor
Daria Mochly-Rosen
Joan J. Kendig
Sarah M. Sweitzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2524818A1 publication Critical patent/CA2524818A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition destinée à être utilisée pour gérer le sevrage d'une substance engendrant une dépendance. La composition comprend un ou plusieurs peptides possédant une activité spécifique pour isozyme .epsilon. et/ou ? de protéine kinase C (PKC). Le ou les peptide(s) peuvent être administrés avant, pendant ou après l'administration de la substance engendrant la dépendance. L'invention concerne aussi un kit possédant au moins un récipient contenant un peptide possédant une activité spécifique pour isozyme .epsilon. et/ou ? de protéine kinase C (PKC) et un mode d'emploi.
CA002524818A 2003-05-16 2003-05-16 Peptides de proteine kinase c utilises pour le sevrage Abandoned CA2524818A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/016070 WO2004103266A2 (fr) 2003-05-16 2003-05-16 Peptides de proteine kinase c utilises pour le sevrage

Publications (1)

Publication Number Publication Date
CA2524818A1 true CA2524818A1 (fr) 2004-12-02

Family

ID=33476226

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002524818A Abandoned CA2524818A1 (fr) 2003-05-16 2003-05-16 Peptides de proteine kinase c utilises pour le sevrage

Country Status (5)

Country Link
EP (1) EP1631309A4 (fr)
JP (1) JP4675109B2 (fr)
AU (1) AU2003241559A1 (fr)
CA (1) CA2524818A1 (fr)
WO (1) WO2004103266A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519391A (ja) * 1998-07-06 2002-07-02 オー． メッシング，ロバート 痛みを処置するための、プロテインキナーゼｃイプシロンの阻害剤の使用
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US6717030B2 (en) * 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
US6248904B1 (en) * 1998-07-21 2001-06-19 Cytovia, Inc. Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
CA2785889A1 (fr) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibiteurs peptidiques de la proteine kinase c

Also Published As

Publication number Publication date
AU2003241559A1 (en) 2004-12-13
JP4675109B2 (ja) 2011-04-20
EP1631309A2 (fr) 2006-03-08
WO2004103266A2 (fr) 2004-12-02
JP2006525948A (ja) 2006-11-16
WO2004103266A8 (fr) 2005-10-20
EP1631309A4 (fr) 2010-04-28
WO2004103266A3 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
US8507440B2 (en) Protein kinase C peptides for use in withdrawal
CA2481512C (fr) Inhibiteurs peptidiques de la proteine kinase c.gamma. pour la ge stion de la douleur
Tian et al. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat
Roumy et al. Neuropeptide FF, pain and analgesia
Gerrits et al. Drug dependence and the endogenous opioid system
Narita et al. Role of protein kinase C in desensitization of spinal δ‐opioid‐mediated antinociception in the mouse
Steele et al. A possible role for the brain renin-angiotensin system in the regulation of LH secretion
Marco et al. Neuropeptide FLFQPQRFamide receptors within the ventral mesenchephalon and dopaminergic terminal areas: Localization and functional antiopioid involvement
Pastor et al. Effect of selective antagonism of mu (1)-, mu (1/2)-, mu (3)-, and delta-opioid receptors on the locomotor-stimulating actions of ethanol
WO2005032575A1 (fr) Peptides de la proteine kinase c utiles pendant le sevrage
CA2524818A1 (fr) Peptides de proteine kinase c utilises pour le sevrage
Szekely Opioid peptides in substance abuse
Menendez et al. Calmodulin inhibitors induce spinal analgesia in rats
JP2010090176A (ja) 離脱症状における使用のためのプロテインキナーゼｃペプチド
Buccafusco et al. Effect of intrathecal pretreatment with the neurokinin receptor antagonist CP-99994 on the expression of naloxone-precipitated morphine withdrawal symptoms
WO1997049422A1 (fr) Procede d'utilisation de ligands du recepteur opioïde kappa
Attila et al. The antiopioid peptide, neuropeptide FF, enhances the effects of acute morphine on the cerebral monoamines in rats
Khasar et al. Sympathetic-independent bradykinin mechanical hyperalgesia induced by subdiaphragmatic vagotomy in the rat
Hutcheson et al. Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception
Yoburn Opioid antagonist-induced upregulation and functional supersensitivity
Gulati Differential effects of intrahypothalamic administration of opioids on food intake in naive and tolerant rats
Prupas Modulation of behavioural and neurochemical responses associated with morphine tolerance by ultra-low doses of opioid receptor antagonists.
Herz Opposing tonically active endogenous opioid system modulating the mesolimbic dopamine reward pathway
AU2012216402A1 (en) Peptide inhibitors of protein kinase Cy for pain management
Zachariou Studies on the modulation of the basal and evoked release of substance P in the dorsal horn of the rat

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead